Bio Expo Online

Search Available Compounds by Structure

List Your Company
Advertise Here
Submit Press Release

SEARCH Bio Expo Online

Home News Search Register Login

Bio Expo Online

Compound Libraries

03.11.2004 Norak Biosciences announced the signing of a second license agreement with AstraZeneca to continue use of Transfluor(R) Technology in its G protein-coupled receptor (GPCR) drug discovery program.:
AstraZeneca will use Transfluor to advance novel lead compounds discovered from a primary high throughput screen utilizing Transfluor under an agreement announced in June 2002. The terms of the 2002 agreement called for Norak to develop a cell line for an AstraZeneca GPCR target of interest that was then screened by AstraZeneca. NB-PR 11/3/04

new | february 2007 | january 2007 | september 2006 | august 2006 | july 2006 | june 2006 | may 2006 | april 2006 | march 2006 | january 2006 | november 2005 | august 2005 | july 2005 | june 2005 | may 2005 | april 2005 | march 2005 | december 2005 | november 2004




Category List
A to Z Company List
Allied Services
Building Blocks
cGMP
Software
Company Type
Contract Research, Procurement Services
Custom Synthesis
Logistics, Packaging, Shipping
Name Reactions
Natural Products
Process Services
Regional
Scientific Equipment
Screening Compounds
Specialty Chemicals
Volume Capacity
Web Links
Conferences and Trade Shows

News and Events

Media Partners
Become a Partner



Our Services
Register your company
Link exchange
Advertise with us
Term of use
Contact us

Featured Links

MyriaScreen
LOPAC 1280
Search by Structure
Bioscreening News
Chemical Reagents
Chemistry Software
Chemistry Databases

Home | News | Advanced Search | List Your Company | Advertising | Terms | Account Login | Contact Us

2004-2007 BioScreening.com, All Rights Reserved